☆ 4.7 Article

Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

EUROPEAN JOURNAL OF CANCER (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Antoinette R. Tan et al.

Summary: The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection has been shown to be non-inferior to intravenous administration in terms of efficacy, leading to FDA approval. Safety profile is similar to other studies involving pertuzumab, trastuzumab, and chemotherapy. Ongoing follow-up is focused on long-term outcomes and safety.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Flexible care in breast cancer

A. Wardley et al.

Summary: Flexible care, which brings cancer treatment closer to patients' homes or workplaces, reduces burden on patients and expands treatment capacity. Subcutaneous administration of trastuzumab is well suited for flexible care and can be effectively administered in the patient's home, primary care settings or local hospitals.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

The oncology hospital at home: Health care utilization outcomes from the huntsman at home trial.

Kathi Mooney et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F. Cardoso et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Medicine, Research & Experimental

Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site

Iris Usach et al.

ADVANCES IN THERAPY (2019)

添加到收藏夹

Article Oncology

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

H. J. Burstein et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20_ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

M. Rummel et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

Erwin De Cock et al.

CANCER MEDICINE (2016)

添加到收藏夹

Article Oncology

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

X. Pivot et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Xavier Pivot et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

Review Oncology

Catheter-Associated Thrombosis in Patients With Malignancy

Sudeep P. Shivakumar et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.